Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial-Reference-Cited by-同舟云学术

Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial

Published:2017-06-21 Issue:6 Volume:141 Page:1249-1256
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Han Baohui¹^ORCID,Jin Bo¹,Chu Tianqing¹,Niu Yanjie¹,Dong Yu¹,Xu Jianlin¹,Gu Aiqing¹,Zhong Hua¹,Wang Huimin¹,Zhang Xueyan¹,Shi Chunlei¹,Zhang Yanwei¹,Zhang Wei¹,Lou Yuqing¹,Zhu Lei²,Pei Jun¹

Affiliation:

1. Department of Pulmonary; Shanghai Chest Hospital, Shanghai Jiaotong University; Shanghai China

2. Department of Pathology; Shanghai Chest Hospital, Shanghai Jiaotong University; Shanghai China

Funder

Key Projects of the Biomedicine Department, Science and Technology Commission of Shanghai Municipality

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference37 articles.

1. Global cancer statistics, 2012;Torre;CA Cancer J Clin,2015

2. Annual report on status of cancer in China, 2011;Chen;Chin J Cancer Res,2015

3. A systematic review of the characteristics associated with recall rates, detection rates and positive predictive values of computed tomography screening for lung cancer;Seigneurin;Ann Oncol,2014

4. The new concepts on overcoming drug resistance in lung cancer;Zhang;Drug Des Dev Ther,2014

5. Chemotherapy remains an essential element of personalized care for persons with lung cancers;Hellmann;Ann Oncol,2016

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meta-analysis of Targeted Therapies in EGFR-mutated Non–Small Cell Lung Cancer;American Journal of Clinical Oncology;2024-09-11

2. EGFR-TKIs or EGFR-TKIs combination treatments for untreated advanced EGFR- mutated NSCLC: a network meta-analysis;2024-09-11

3. Novel Combination of Therapeutic Approaches in Advanced NSCLC with EGFR Activating Mutations;Targets;2024-09-07

4. Efficacy and safety of a novel TKI (anlotinib) for the treatment of advanced digestive system neoplasms: a systematic review and meta-analysis;Frontiers in Immunology;2024-08-14

5. “Tumor-free survival” Does Not Outweigh the Adverse Effects of Anti-EGFR Therapy and Chemotherapy in Patients With NSCLC;Journal of Thoracic Oncology;2024-08